Search Results - "Wang, Cathy S"
-
1
Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
Published in Haematologica (Roma) (01-04-2017)“…B-cell maturation antigen is expressed on plasma cells. In this study, we have identified serum B-cell maturation antigen as a novel biomarker that can monitor…”
Get full text
Journal Article -
2
Multiscale profiling of protease activity in cancer
Published in Nature communications (03-10-2022)“…Diverse processes in cancer are mediated by enzymes, which most proximally exert their function through their activity. High-fidelity methods to profile enzyme…”
Get full text
Journal Article -
3
Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma
Published in Clinical cancer research (01-07-2016)“…Reduced uninvolved immunoglobulin (Ig) levels are a hallmark of multiple myeloma. We previously showed that B-cell maturation antigen (BCMA) is solubilized and…”
Get full text
Journal Article -
4
Aging and matrix viscoelasticity affect multiscale tendon properties and tendon derived cell behavior
Published in Acta biomaterialia (15-04-2022)“…Aging is the largest risk factor for Achilles tendon associated disorders and rupture. Although Achilles tendon macroscale elastic properties are suggested to…”
Get full text
Journal Article -
5
JAK1/2 pathway inhibition suppresses M2 polarization and overcomes resistance of myeloma to lenalidomide by reducing TRIB1, MUC1, CD44, CXCL12, and CXCR4 expression
Published in British journal of haematology (01-01-2020)“…Summary Monocytes polarize into pro‐inflammatory macrophage‐1 (M1) or alternative macrophage‐2 (M2) states with distinct phenotypes and physiological…”
Get full text
Journal Article -
6
Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival
Published in British journal of haematology (01-09-2012)“…Summary Although TNFRSF17 (also designated as B‐cell maturation antigen (BCMA)) is expressed on tumour cells in B‐cell malignancies, it has not been found in…”
Get full text
Journal Article -
7
Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand‐1 (PD‐L1) expression and increases anti‐tumour effects of T cells in multiple myeloma
Published in British journal of haematology (01-02-2021)“…Summary Multiple myeloma (MM) tumour cells evade host immunity through a variety of mechanisms, which may potentially include the programmed cell death…”
Get full text
Journal Article -
8
Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells
Published in Leukemia research (01-06-2019)“…•Patients with BCMA ≥156 ng/mL have decreased anti-BCMA binding to MM tumor cells.•Circulating BCMA levels in the majority of RRMM patients are…”
Get full text
Journal Article -
9
The JAK1/2 inhibitor ruxolitinib downregulates the immune checkpoint protein B7H3 in multiple myeloma
Published in Hematological oncology (01-08-2023)“…We hypothesized that ruxolitinib may inhibit the immune checkpoint protein, B7H3; and, thus, investigated its effects on this immune inhibitor using multiple…”
Get full text
Journal Article -
10
The clinical significance of B-cell maturation antigen as a therapeutic target and biomarker
Published in Expert review of molecular diagnostics (03-04-2018)“…B-cell maturation antigen (BCMA) is a cell membrane bound tumor necrosis factor receptor family member that is expressed exclusively on late stage normal and…”
Get more information
Journal Article -
11
Anti-Angiogenic and Anti-Multiple Myeloma Effects of Oprozomib (OPZ) Alone and in Combination with Pomalidomide (Pom) and/or Dexamethasone (Dex)
Published in Leukemia research (01-06-2017)“…Highlights • Oprozomib (OPZ) shows anti-tumor activity in human multiple myeloma (MM) xenograft models • OPZ is an oral proteasome inhibitor that shows…”
Get full text
Journal Article -
12
Combined TRAF6 Targeting and Proteasome Blockade Has Anti-myeloma and Anti-Bone Resorptive Effects
Published in Molecular cancer research (01-05-2017)“…TNF receptor-associated factor 6 (TRAF6) has been implicated in polyubiquitin-mediated IL1R/TLR signaling through activation of kinase (IKK) to regulate the…”
Get full text
Journal Article -
13
Protease Activity Analysis: A Toolkit for Analyzing Enzyme Activity Data
Published in ACS omega (19-07-2022)“…Analyzing the activity of proteases and their substrates is critical to defining the biological functions of these enzymes and to designing new diagnostics and…”
Get full text
Journal Article -
14
The Role of B-Cell Maturation Antigen in the Biology and Management of, and as a Potential Therapeutic Target in, Multiple Myeloma
Published in Targeted oncology (01-02-2018)“…B-cell maturation antigen (BCMA) was originally identified as a cell membrane receptor, expressed exclusively on late stage B-cells and plasma cells (PCs)…”
Get full text
Journal Article -
15
Pleiotrophin produced by multiple myeloma induces transdifferentiation of monocytes into vascular endothelial cells: a novel mechanism of tumor-induced vasculogenesis
Published in Blood (26-02-2009)“…Enhanced angiogenesis is a hallmark of cancer. Pleiotrophin (PTN) is an angiogenic factor that is produced by many different human cancers and stimulates tumor…”
Get full text
Journal Article -
16
A novel angiogenesis model for screening anti-angiogenic compounds: The chorioallantoic membrane/feather bud assay
Published in International journal of oncology (01-07-2010)“…Enhanced angiogenesis is a hallmark of solid tumors and hematological malignancies. Anti-angiogenic therapeutic approaches have recently been shown to be…”
Get full text
Journal Article -
17
Pleiotrophin is highly expressed by myeloma cells and promotes myeloma tumor growth
Published in Blood (01-07-2007)“…Pleiotrophin (PTN) is an important developmental cytokine that is highly expressed during embryogenesis but shows very limited expression in adult tissues,…”
Get full text
Journal Article -
18
Effects of INCB052793, a Selective JAK1 Inhibitor, in Combination with Anti-Myeloma Agents on Human Multiple Myeloma (MM) In Vitro and In Vivo
Published in Blood (02-12-2016)“…Introduction: Several studies have demonstrated constitutive activation of the JAK-STAT pathway in MM through dysregulated signaling of cytokines such as IL-6…”
Get full text
Journal Article -
19
Baseline and Early Changes in Serum B-Cell Maturation Antigen Levels Predict Progression Free Survival and Response Status for Multiple Myeloma Patients in a Phase 1 Trial Evaluating Ruxolitinib, Lenalidomide and Methylprednisolone
Published in Blood (29-11-2018)“…Background: B-cell maturation antigen (BCMA) is highly expressed on malignant plasma cells from patients with multiple myeloma (MM). We have previously shown…”
Get full text
Journal Article -
20
Baseline and Increases in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Relapsed/Refractory Multiple Myeloma Patients Undergoing New Treatments
Published in Blood (13-11-2019)“…Introduction: B-cell maturation antigen (BCMA) is a protein that is expressed on malignant plasma cells from patients (pts) with multiple myeloma (MM). Our…”
Get full text
Journal Article